The word “platform” may be almost a cliche in the CDMO world by this point. But it can also be the key to successful commercialization.
Viralgen Chief Commercial Officer Andy Holt tackles this topic in his 2026 Outsourced Pharma Capacity Update, focusing on platforms—and Viralgen’s Aava™ AAV manufacturing platform in particular—as an engine for generating the kind of prior knowledge that drives regulatory conversations.
He also talks about something else that Aava means: the ability to go from idea to IND in less than a year. And along the way he touches on some of the markers of Viralgen’s successful platform approach:
-
49/49 successful client IND submissions
-
2,000+ AAV batches
-
100+ cBMP runs at 250/500L scale
Dig even deeper in the video below.
